These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
486 related articles for article (PubMed ID: 15273714)
1. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714 [TBL] [Abstract][Full Text] [Related]
2. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401 [TBL] [Abstract][Full Text] [Related]
3. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848 [TBL] [Abstract][Full Text] [Related]
4. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773 [TBL] [Abstract][Full Text] [Related]
5. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
6. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma. Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862 [TBL] [Abstract][Full Text] [Related]
7. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675 [TBL] [Abstract][Full Text] [Related]
8. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990 [TBL] [Abstract][Full Text] [Related]
9. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191 [TBL] [Abstract][Full Text] [Related]
11. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Jantunen E; Kuittinen T; Nousiainen T Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867 [TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161 [TBL] [Abstract][Full Text] [Related]
13. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Jantunen E; Mahlamäki E; Nousiainen T Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654 [TBL] [Abstract][Full Text] [Related]
14. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N; Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926 [TBL] [Abstract][Full Text] [Related]
15. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
17. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630 [TBL] [Abstract][Full Text] [Related]
19. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089 [TBL] [Abstract][Full Text] [Related]
20. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Samaras P; Buset EM; Siciliano RD; Haile SR; Petrausch U; Mischo A; Honegger H; Pestalozzi BC; Schanz U; Stussi G; Stahel RA; Knuth A; Renner C; Stenner-Liewen F Oncology; 2010; 79(1-2):93-7. PubMed ID: 21079406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]